Research News

Orchiectomy has fewer adverse effects than chemical castration for metastatic prostate cancer

BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h6966 (Published 24 December 2015) Cite this as: BMJ 2015;351:h6966
  1. Jacqui Wise
  1. 1London

Medical castration is associated with a higher risk of adverse effects than surgical castration in men with metastatic prostate cancer, research published in JAMA Oncology has found.1

Androgen deprivation therapy is a mainstay in the treatment of prostate cancer and can be achieved either surgically or pharmacologically with gonadotrophin releasing hormone analogues (GnRHa). In recent years medical castration has largely replaced …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe